An analysis of the reported association of oral contraceptives to thromboembolic disease.
D000293:Adolescent; D000328:Adult; D002561:Cerebrovascular Disorders / Q000139:chemically induced; D003276:Contraceptives, Oral / Q000009:adverse effects*; D004054:Diethylstilbestrol / Q000009:adverse effects / Q000627:therapeutic use; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000139:chemically induced / Q000401:mortality; D008297:Male; D008656:Mestranol / Q000009:adverse effects; D009203:Myocardial Infarction / Q000139:chemically induced; D009641:Norethynodrel / Q000009:adverse effects; D011247:Pregnancy; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011655:Pulmonary Embolism / Q000139:chemically induced / Q000401:mortality; D012008:Recurrence; D012189:Retrospective Studies; D013923:Thromboembolism / Q000139:chemically induced* / Q000453:epidemiology / Q000401:mortality; D013924:Thrombophlebitis / Q000139:chemically induced / Q000453:epidemiology; D006113:United Kingdom
D003276:Contraceptives, Oral; D004967:Estrogens; D004054:Diethylstilbestrol; D009641:Norethynodrel; D008656:Mestranol